Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice

Vaccine

Volumn 32, Issue 8, 2014, Pages 949-956

  Wang, Hong Jiang ^a   Li, Xiao Feng ^a   Ye, Qing ^a   Li, Shi Hua ^a   Deng, Yong Qiang ^a   Zhao, Hui ^a   Xu, Yan Peng ^a   Ma, Jie ^a   Qin, E De ^a   Qin, Cheng Feng ^a,b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Chimeric flavivirus; Japanese encephalitis virus; Tick borne encephalitis virus; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; JAPANESE ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT TICK BORNE ENCEPHALITIS VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHIMERA; CONTROLLED STUDY; DOSE RESPONSE; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; INOCULATION; MAMMAL CELL; MOSQUITO; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; STRUCTURAL GENE; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS IMMUNITY; VIRUS REPLICATION;

CHIMERIC FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; TICK-BORNE ENCEPHALITIS VIRUS; VACCINE;

AEDES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CRICETINAE; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS VIRUSES, TICK-BORNE; ENCEPHALITIS, JAPANESE; ENCEPHALITIS, TICK-BORNE; IMMUNOGLOBULIN G; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VERO CELLS;

EID: 84892995375     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.050     Document Type: Article

References (51)

1. Poponnikova T.V. Specific clinical and epidemiological features of tick-borne encephalitis in Western Siberia. Int J Med Microbiol 2006, 296(Suppl 40):59-62.
2. Gritsun T.S., Lashkevich V.A., Gould E.A. Tick-borne encephalitis. Antiviral Res 2003, 57:129-146.
3. Lindquist L., Vapalahti O. Tick-borne encephalitis. Lancet 2008, 371:1861-1871.
4. Mandl C.W. Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis. Virus Res 2005, 111:161-174.
5. Kaiser R. Tick-borne encephalitis. Infect Dis Clin North Am 2008, 22:561-575. x.
6. Suss J. Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview. Ticks Tick Borne Dis 2011, 2:2-15.
7. Mansfield K.L., Johnson N., Phipps L.P., Stephenson J.R., Fooks A.R., Solomon T. Tick-borne encephalitis virus-a review of an emerging zoonosis. J Gen Virol 2009, 90:1781-1794.
8. Ecker M., Allison S.L., Meixner T., Heinz F.X. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J Gen Virol 1999, 80(Pt 1):179-185.
9. Zent O., Broker M. Tick-borne encephalitis vaccines: past and present. Expert Rev Vaccines 2005, 4:747-755.
10. Leonova G.N., Pavlenko E.V. Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human. Vaccine 2009, 27:2899-2904.
11. Heinz F.X., Holzmann H., Essl A., Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 2007, 25:7559-7567.
12. Pavlova B.G., Loew-Baselli A., Fritsch S., Poellabauer E.M., Vartian N., Rinke I., et al. Tolerability of modified tick-borne encephalitis vaccine FSME-IMMUN "NEW" in children: results of post-marketing surveillance. Vaccine 2003, 21:742-745.
13. Zent O., Banzhoff A., Hilbert A.K., Meriste S., Sluzewski W., Wittermann C. Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer. Vaccine 2003, 21:3584-3592.
14. Bender A., Jager G., Scheuerer W., Feddersen B., Kaiser R., Pfister H.W. Two severe cases of tick-borne encephalitis despite complete active vaccination-the significance of neutralizing antibodies. J Neurol 2004, 251:353-354.
15. Kleiter I., Jilg W., Bogdahn U., Steinbrecher A. Delayed humoral immunity in a patient with severe tick-borne encephalitis after complete active vaccination. Infection 2007, 35:26-29.
16. Kunze U., Baumhackl U., Bretschneider R., Chmelik V., Grubeck-Loebenstein B., Haglund M., et al. The golden agers and tick-borne encephalitis. Conference report and position paper of the International Scientific Working Group on Tick-borne encephalitis. Wien Med Wochenschr 2005, 155:289-294.
17. Stiasny K., Holzmann H., Heinz F.X. Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs. Vaccine 2009, 27:7021-7026.
18. Grgic-Vitek M., Avsic-Zupanc T., Klavs I. Tick-borne encephalitis after vaccination: vaccine failure or misdiagnosis. Vaccine 2010, 28:7396-7400.
19. Andersson C.R., Vene S., Insulander M., Lindquist L., Lundkvist A., Gunther G. Vaccine failures after active immunisation against tick-borne encephalitis. Vaccine 2010, 28:2827-2831.
20. Plisek S., Honegr K., Beran J. TBE infection in an incomplete immunized person at-risk who lives in a high-endemic area-impact on current recommendations for immunization of high-risk groups. Vaccine 2008, 26:301-304.
21. Kofler R.M., Heinz F.X., Mandl C.W. Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence. J Virol 2002, 76:3534-3543.
22. Heiss B.L., Maximova O.A., Thach D.C., Speicher J.M., Pletnev A.G. MicroRNA targeting of neurotropic flavivirus: effective control of virus escape and reversion to neurovirulent phenotype. J Virol 2012, 86:5647-5659.
23. Heiss B.L., Maximova O.A., Pletnev A.G. Insertion of microRNA targets into the flavivirus genome alters its highly neurovirulent phenotype. J Virol 2011, 85:1464-1472.
24. Wright P.F., Ankrah S., Henderson S.E., Durbin A.P., Speicher J., Whitehead S.S., et al. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Vaccine 2008, 26:882-890.
25. Rumyantsev A.A., Chanock R.M., Murphy B.R., Pletnev A.G. Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys. Vaccine 2006, 24:133-143.
26. Pletnev A.G., Men R. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. PNAS 1998, 95:1746-1751.
27. Pletnev A.G., Karganova G.G., Dzhivanyan T.I., Lashkevich V.A., Bray M. Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus. Virology 2000, 274:26-31.
28. Yu Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 2010, 28:3635-3641.
29. Tandan J.B., Ohrr H., Sohn Y.M., Yoksan S., Ji M., Nam C.M., et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 2007, 25:5041-5045.
30. Kumar R., Tripathi P., Rizvi A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 2009, 360:1465-1466.
31. Hennessy S., Liu Z., Tsai T.F., Strom B.L., Wan C.M., Liu H.L., et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996, 347:1583-1586.
32. Gatchalian S., Yao Y., Zhou B., Zhang L., Yoksan S., Kelly K., et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 2008, 26:2234-2241.
33. Bista M.B., Banerjee M.K., Shin S.H., Tandan J.B., Kim M.H., Sohn Y.M., et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001, 358:791-795.
34. Li S.H., Dong H., Li X.F., Xie X., Zhao H., Deng Y.Q., et al. Rational design of a flavivirus vaccine by abolishing viral RNA 2'-O methylation. J Virol 2013, 87:5812-5819.
35. Si B.Y., Jiang T., Zhang Y., Deng Y.Q., Huo Q.B., Zheng Y.C., et al. Complete genome sequence analysis of tick-borne encephalitis viruses isolated in northeastern China. Arch Virol 2011, 156:1485-1488.
36. Ye Q., Li X.F., Zhao H., Li S.H., Deng Y.Q., Cao R.Y., et al. A single nucleotide mutation in NS2A of Japanese encephalitis-live vaccine virus (SA14-14-2) ablates NS1' formation and contributes to attenuation. J Gen Virol 2012, 93:1959-1964.
37. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
38. Amberg S.M., Rice C.M. Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing. J Virol 1999, 73:8083-8094.
39. Yamshchikov V.F., Compans R.W. Formation of the flavivirus envelope: role of the viral NS2B-NS3 protease. J Virol 1995, 69:1995-2003.
40. Lobigs M., Lee E. Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes. J Virol 2003, 78:178-186.
41. Pletnev A.G., Putnak R., Speicher J., Wagar E.J., Vaughn D.W. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. PNAS 2002, 99:3036-3041.
42. Chambers T.J., Nestorowicz A., Mason P.W., Rice C.M. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 1999, 73:3095-3101.
43. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000, 74:5477-5485.
44. Engel A.R., Mitzel D.N., Hanson C.T., Wolfinbarger J.B., Bloom M.E., Pletnev A.G. Chimeric tick-borne encephalitis/dengue virus is attenuated in Ixodes scapularis ticks and Aedes aegypti mosquitoes. Vector Borne Zoonotic Dis 2011, 11:665-674.
45. Whitehead S.S., Hanley K.A., Blaney J.E., Gilmore L.E., Elkins W.R., Murphy B.R. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003, 21:4307-4316.
46. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001, 65:405-413.
47. Huang C.Y., Butrapet S., Pierro D.J., Chang G.J., Hunt A.R., Bhamarapravati N., et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 2000, 74:3020-3028.
48. Pletnev A.G., Bray M., Huggins J., Lai C.J. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. PNAS 1992, 89:10532-10536.
49. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004, 78:12497-12507.
50. Huang C.Y., Silengo S.J., Whiteman M.C., Kinney R.M. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J Virol 2005, 79:7300-7310.
51. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201:370-377.